ClearPoint Neuro announced it has initiated the Limited Market Release for its SmartFrame OR Stereotactic System.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLPT:
- ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
- ClearPoint congratulates partner PTC Therapeutics on completion of its BLA
- ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
- ClearPoint Neuro price target raised to $9 from $8 at Stifel
- ClearPoint Neuro reports Q4 revenue $6.8M, consensus $6.53M